Metformin: beyond the glycemic target

dc.creatorMorantes-Caballero, Jairo A
dc.creatorLondoño-Zapata, Gabriel A.
dc.creatorRubio-Rivera, Manuela
dc.creatorPinilla-Roa, Análida Elizabeth
dc.date2017-04-28
dc.date.accessioned2022-03-14T20:12:19Z
dc.date.available2022-03-14T20:12:19Z
dc.descriptionLa metformina es una biguanida que disminuye gluconeogénesis e incrementa la recaptación de glucosa en los músculos, sin embargo, más allá del glucémico se han documentado beneficios adicionales como la disminución de complicaciones crónicas derivadas de la hiperglucemia, entre ellas las cardiovasculares y del síndrome metabólico per se. Objetivo: identificar los efectos de la metformina diferentes al control control glucémico en población con diabetes mellitus, con el fin de contribuir a difundir el conocimiento. Materialesy método: tres revisores independientes realizaron la búsqueda en distintas bases de datos entre ellas Pubmed y ScienceDirect, utilizando los términos Metfomin AND Cardiovascular disease AND inflamatory response AND Hyperlipidemia, Biguanides, Diabetes Mellitus, Diabetes complications, Obesity, Vascular diseases AND Cancer; y Metfomina y enfermedad cardiovascular, metformina y cáncer se seleccionaron los artículos desde el año 2010, encontrando 13 828 artículos, de los cuales se incluyeron 144. Conclusión: más allá del control glucémico, la metformina, modifica la “memoria metabólica”, reduce mediadores inflamatorios y el grosor de pared arterial, disminuye factorestrombóticos y reduce la prevalencia de falla cardiaca logrando impactar la morbimortalidad y mediante cambios moleculares o genéticos, tiene potencial uso como anticancerígeno. El clínico debe conocer estos efectos para favorecer su pronto inicio en los casos indicados. MÉD.UIS. 2017;30(1):57-71.Palabras clave: Metformina. Diabetes Mellitus. Proteínas Quinasas Activada por AMP. Obesidad. Enfermedades Vasculares. Neoplasias.es-ES
dc.descriptionthe metformin is a biguanide which main action is to decrease hepatic glucose output, primarily by decreasing gluconeogenesis, and increase glucose uptake by muscles. However, beyond the glycemic target, additional benefits have been documented like a decrease in chronic complications to hyperglycemia, including cardiovascular comorbility and metabolic syndrome. Objetive: to identifyeffects of metformin other than glycemic control in patients with diabetes mellitus in order to help disseminate knowledge. Materials and methods: three independent reviewers searched in different databases of PubMed and ScienceDirect using the DeCS and MeSH terms: Metfomin AND Cardiovascular disease AND inflamatory response AND Hyperlipidemia, Biguanides, Diabetes Mellitus, Diabetes complications,Obesity, Vascular diseases AND Cancer, selecting the items since 2010 year and prior to warrant mention. Search based publications that were considered most relevant and, additionally, a manual search of the referenced articles in publications retrieved in the initial search was conducted, 13 828 articles were found but 144 were included finally. Conclusion: beyond glycemic control, Metformin, modifies the “metabolic memory”, reduces inflammatory mediators and thickness of arterial wall, decreases thrombotic factors and reduces the prevalence of heart failure making an impact morbidity and mortality and because of molecular or genetic changes, it has potential use as anticarcinogenic. The physicians should know it to facilitate the early administration of this medication when it is indicated.MÉD.UIS. 2017;30(1):57-71.Keywords: Metformin. Diabetes Mellitus. AMP-Activated Protein Kinases. Neoplasms. Obesity. Vascular Diseases.en-US
dc.formatapplication/pdf
dc.formattext/html
dc.identifierhttps://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/6308
dc.identifier.urihttps://noesis.uis.edu.co/handle/20.500.14071/5892
dc.languagespa
dc.publisherUniversidad Industrial de Santanderes-ES
dc.relationhttps://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/6308/6532
dc.relationhttps://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/6308/7008
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rights.licenseAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)
dc.sourceRevista Médicas UIS; v. 30 n. 1 (2017): Médicas UIS; 57-71pt-BR
dc.sourceMédicas UIS; Vol. 30 No. 1 (2017): Médicas UIS; 57-71en-US
dc.sourceMédicas UIS; Vol. 30 Núm. 1 (2017): Médicas UIS; 57-71es-ES
dc.source1794-5240
dc.source0121-0319
dc.titleMetformin: beyond the glycemic targeten-US
dc.titleMetformina: más allá del control glucémicoes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dspace.entity.type
Files
Collections